The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: Results of a randomized, vehicle-controlled study

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 65, Issue 12, 2010, Pages 1594-1599

  Foelster Holst, R ^a   Reitamo, S ^b   Yankova, R ^c   Worm, M ^d   Kadurina, M ^e   Thaci, K ^f   Bieber, T ^g   Tsankov, N ^h   Enk, A ⁱ   Luger, T ^j   Duffy, M ^k   Tansley, R ^k  

^a UK S H   (Germany)

^b Iho ja Allergiasairaala   (Finland)

^c Clin of Dermatology and Venereology   (Bulgaria)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Kinika Po Dematologia   (Bulgaria)

^f GOETHE UNIVERSITY   (Germany)

^g UNIVERSITY OF BONN   (Germany)

^h Clinic for Dermatology and Venereology   (Bulgaria)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j UNIVERSITY OF MÜNSTER   (Germany)

^k Serentis Ltd   (United Kingdom)

more..

Author keywords

Atopic dermatitis; Protease inhibitors; Randomized

Indexed keywords

AUREOLYSIN; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE; PLACEBO; SRD 441; UNCLASSIFIED DRUG;

ADULT; APPLICATION SITE DERMATITIS; APPLICATION SITE DRYNESS; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; APPLICATION SITE SWELLING; APPLICATION SITE URTICARIA; ARTICLE; ATOPIC DERMATITIS; BULGARIA; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FINLAND; GERMANY; HUMAN; MALE; MULTICENTER STUDY; OINTMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF EVALUATION; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

ADULT; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; OINTMENTS; PROTEASE INHIBITORS;

EID: 78349260461     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2010.02417.x     Document Type: Article

References (16)

1. Larsen FS, Hanifin JM,. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am 2002; 22: 1 -24.
2. Buys LM,. Treatment options for atopic dermatitis. Am Fam Physician 2007; 75: 523 -528.
3. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, etal. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441 -446. Epub 2006 Mar 19.
4. Bieber T,. Atopic Dermatitis. N Engl J Med 2008; 358: 1483 -1494.
5. Walley AJ, Chavanas S, Moffatt MF, etal. Gene polymorphism in Netherton and common atopic disease. Nat Med 2001; 29: 175 -178.
6. Wachter AM, Lezdey J,. Treatment of atopic dermatitis with alpha 1-proteinase inhibitor. Ann Allergy 1992; 69: 407 -414.
7. Harper JI, Godwin H, Green A, Wilkes LE, Holden NJ, Moffatt M, etal. A study of matrix metalloproteinase expression and activity in atopic dermatitis using a novel skin wash sampling assay for functional biomarker analysis. Br J Dermatol 2010; 162: 397 -403.
8. Leyden JJ, Marples RR, Kligman AM,. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 1974; 90: 525 -530.
9. Guzik TJ, Bzowska M, Kasprowicz A, etal. Persistent skin colonization with Staphylococcus aureus in atopic dermatitis: relationship to clinical and immunological parameters. Clin Exp Allergy 2005; 35: 448 -455.
10. Miedzobrodzki J, Kaszycki P, Bialecka A, etal. Proteolytic activity of Staphylococcus aureus strains isolated from the colonized skin of patients with acute-phase atopic dermatitis. Eur J Clin Microbiol Infect Dis 2002; 21: 269 -276.
11. Lomholt H, Andersen KE, Kilian M,. Staphylococcus aureus clonal dynamics and virulence factors in children with atopic dermatitis. J Invest Dermatol 2005; 125: 977 -982.
12. Dubin G,. Extracellular proteases of Staphylococcus spp. Biol Chem 2002; 383: 1075 -1086.
13. Shaw L, Golonka E, Potempa J, etal. The role and regulation of the extracellular proteases of Staphylococcus aureus. Microbiology 2004; 150: 217 -228.
14. Okamoto T, Akaike T, Suga M, etal. Activation of human matrix metalloproteinases by various bacterial proteinases. J Biol Chem 1997; 272: 6059 -6066.
15. Sieprawska-Lupa M, Mydel P, Krawczyk K, etal. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob Agents Chemother 2004; 48: 4673 -4679.
16. Ong PY, Ohtake T, Brandt C, etal. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347: 1151 -1160.